ArticleClinical and experimental medicine2025
Analysis of prognostic factors affecting TA-TMA patients: a single-center retrospective study.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTransplantation-associated thrombotic microangiopathy (TA-TMA) is a severe thrombotic complication that occurs after hematopoietic stem cell transplantation. Currently, there are no clear conclusions on the factors influencing the prognosis of TA-TMA patients and the best treatment plan for TA-TMA.
methodsWe retrospectively collected information on 26 patients with TA-TMA from a single center. The independent factors affecting prognosis were analyzed through univariate and multivariate Cox regression. Subgroup analysis was also conducted to investigate the impact of different treatment methods on overall survival of patients.
resultsWe found that high creatinine levels during the diagnosis of TA-TMA and previous CAR-T cell therapy were independent risk factors affecting the prognosis of TA-TMA patients. Additionally, discontinuing calcineurin inhibitors (CNI) is helpful in prolonging the survival period of TA-TMA patients.
conclusionsOur research has revealed the high-risk factors affecting the survival of TA-TMA patients and the efficacy of different treatment methods, providing guidance for subsequent clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.